Arsanis, Inc. License Agreements
11 Contracts & Agreements
- License Agreement, dated as of November 13, 2020, by and between X4 Pharmaceuticals Inc. and the Dana Farber Cancer Institute (Filed With SEC on March 19, 2021)
- Exclusive License Agreement, dated as of December 23, 2016, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Beth Israel Deaconess Medical Center (Filed With SEC on May 13, 2019)
- License Agreement, dated as of December 13, 2016, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Georgetown University (Filed With SEC on May 13, 2019)
- Amendment No. 1 to License Agreement, dated as of October 23, 2014, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Genzyme Corporation, a Sanofi... (Filed With SEC on May 13, 2019)
- License Agreement, dated as of July 10, 2014, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, LLC) and Genzyme Corp., a Sanofi company (Filed With SEC on May 13, 2019)
- Exclusive License Agreement, dated as of December 23, 2016, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Beth Israel Deaconess Medical Center (Filed With SEC on March 13, 2019)
- License Agreement, dated as of December 13, 2016, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Georgetown University (Filed With SEC on March 13, 2019)
- Amendment No. 1 to License Agreement, dated as of October 23, 2014, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Genzyme Corporation, a Sanofi... (Filed With SEC on March 13, 2019)
- License Agreement, dated as of July 10, 2014, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, LLC) and Genzyme Corp., a Sanofi company (Filed With SEC on March 13, 2019)
- Amendment No. 1 to the Option and License Agreement, dated as of February 27, 2017, by and between the Registrant and Adimab, LLC, dated as of October 13, 2017 (Filed With SEC on October 20, 2017)
- Option and License Agreement, dated as of February 27, 2017, by and between the Registrant and Adimab, LLC (Filed With SEC on October 20, 2017)
